The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma
Multiple myeloma accounts for 1% of all new cancers worldwide. It is the second most common haematological malignancy and has a low five-year survival rate (53.2%). Myeloma remains an incurable disease and is caused by the growth of malignant plasma cells in the bone marrow. Current anti-myeloma the...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/18bb1f7449264767a940c631278022a6 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:18bb1f7449264767a940c631278022a6 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:18bb1f7449264767a940c631278022a62021-11-25T17:02:40ZThe Use of Oncolytic Viruses in the Treatment of Multiple Myeloma10.3390/cancers132256872072-6694https://doaj.org/article/18bb1f7449264767a940c631278022a62021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5687https://doaj.org/toc/2072-6694Multiple myeloma accounts for 1% of all new cancers worldwide. It is the second most common haematological malignancy and has a low five-year survival rate (53.2%). Myeloma remains an incurable disease and is caused by the growth of malignant plasma cells in the bone marrow. Current anti-myeloma therapies (conventional chemotherapies, immunomodulatory drugs i.e., thalidomide and its’ analogues, proteasome inhibitors, monoclonal antibodies, and radiotherapy) initially substantially debulk tumour burden, but after a period of remission ‘plateau phase’ disease invariably relapses due to tumour recrudescence from foci of minimal residual disease (MRD) and accumulating drug resistance. Therefore, there is a compelling clinical need for the development of novel treatment regimens to target MRD and effectively eliminate all remaining tumour cells. This review will discuss the potential use of oncolytic virus (OV) therapies in the treatment of myeloma. Specifically, it will focus on preclinical studies using DNA viruses (adenovirus (Ad), vaccinia virus (VV), myxoma virus (MYXV), and herpes simplex virus (HSV)), RNA viruses (reovirus (reo), coxsackie virus, measles virus (MV) and bovine viral diarrhoea virus (BVDV), and vesicular stomatitis virus (VSV)), and on four types of viruses (VV, reo, MV-NIS and VSV-IFNβ-NIS) that have been assessed clinically in a small number of myeloma patients.Georgia StewartAndrew ChantryMichelle LawsonMDPI AGarticlemultiple myelomaoncolytic virusesDNA virusesRNA virusesreovirusMV-NIS and VSV-IFNβ-NISNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5687, p 5687 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
multiple myeloma oncolytic viruses DNA viruses RNA viruses reovirus MV-NIS and VSV-IFNβ-NIS Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
multiple myeloma oncolytic viruses DNA viruses RNA viruses reovirus MV-NIS and VSV-IFNβ-NIS Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Georgia Stewart Andrew Chantry Michelle Lawson The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma |
| description |
Multiple myeloma accounts for 1% of all new cancers worldwide. It is the second most common haematological malignancy and has a low five-year survival rate (53.2%). Myeloma remains an incurable disease and is caused by the growth of malignant plasma cells in the bone marrow. Current anti-myeloma therapies (conventional chemotherapies, immunomodulatory drugs i.e., thalidomide and its’ analogues, proteasome inhibitors, monoclonal antibodies, and radiotherapy) initially substantially debulk tumour burden, but after a period of remission ‘plateau phase’ disease invariably relapses due to tumour recrudescence from foci of minimal residual disease (MRD) and accumulating drug resistance. Therefore, there is a compelling clinical need for the development of novel treatment regimens to target MRD and effectively eliminate all remaining tumour cells. This review will discuss the potential use of oncolytic virus (OV) therapies in the treatment of myeloma. Specifically, it will focus on preclinical studies using DNA viruses (adenovirus (Ad), vaccinia virus (VV), myxoma virus (MYXV), and herpes simplex virus (HSV)), RNA viruses (reovirus (reo), coxsackie virus, measles virus (MV) and bovine viral diarrhoea virus (BVDV), and vesicular stomatitis virus (VSV)), and on four types of viruses (VV, reo, MV-NIS and VSV-IFNβ-NIS) that have been assessed clinically in a small number of myeloma patients. |
| format |
article |
| author |
Georgia Stewart Andrew Chantry Michelle Lawson |
| author_facet |
Georgia Stewart Andrew Chantry Michelle Lawson |
| author_sort |
Georgia Stewart |
| title |
The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma |
| title_short |
The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma |
| title_full |
The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma |
| title_fullStr |
The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma |
| title_full_unstemmed |
The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma |
| title_sort |
use of oncolytic viruses in the treatment of multiple myeloma |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/18bb1f7449264767a940c631278022a6 |
| work_keys_str_mv |
AT georgiastewart theuseofoncolyticvirusesinthetreatmentofmultiplemyeloma AT andrewchantry theuseofoncolyticvirusesinthetreatmentofmultiplemyeloma AT michellelawson theuseofoncolyticvirusesinthetreatmentofmultiplemyeloma AT georgiastewart useofoncolyticvirusesinthetreatmentofmultiplemyeloma AT andrewchantry useofoncolyticvirusesinthetreatmentofmultiplemyeloma AT michellelawson useofoncolyticvirusesinthetreatmentofmultiplemyeloma |
| _version_ |
1718412761322487808 |